Pfizer Inc. announced positive results from the phase 3 TALAPRO-2 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with Xtandi (enzalutamide), an ...

Pfizer's strong Q4 2024 results showcase growth in cancer drugs and Vyndaqel sales. Learn why PFE stock is a top pick for ...

Pfizer’s PARP inhibitor Talzenna has become the first targeted treatment for HER2-negative locally advanced or metastatic breast cancer with BRCA1/2 mutations to be recommended by NICE for ...

Today, Pfizer said that its phase 3 TALAPRO 2 trial of PARP drug Talzenna (talazoparib) in combination with its Astellas-partnered anti-androgen therapy Xtandi (enzalutamide) reduced radiographic ...

Patients with HRR-deficient metastatic castration-resistant prostate cancer experienced a 14-month gain in OS and a 38% lower death risk with Talzenna plus Xtandi.

This time around, NICE assessed the med using a faster cost comparison process that compared Lynparza to Pfizer’s Talzenna in benefits and cost. Stallergenes Greer’s peanut allergy treatment ...

Tremfya could become the first IL-23 inhibitor with fully subcutaneous induction and maintenance options in the treatment of ...

Pfizer (PFE) will end global development and commercialization of Beqvez, a gene therapy for hemophilia, Nikkei learned Thursday, after the ...

New Diagnostics, AI Breakthroughs, and Next-Gen Therapies Are Transforming the Oncology Market. The oncology sector is experiencing <stron ...

Five-year data from the POETYK PSO long-term extension trial confirm the sustained efficacy and safety of Sotyktu ...